New indication

INTRAN A represents a major breakthrough in the management of chronic myelogenous leukaemia (CML).

With a fundamentally different mode of action to that of cytotoxic agents, INTRAN A can effectively control CML by inducing and maintaining haematological and symptomatic responses. In some patients a cytogenetic response has also been seen.

The subcutaneous route of administration is recommended. This enables patients to self-administer maintenance therapy at home.

Chronic myelogenous leukaemia

Induces and maintains haematological remissions